Compare · ITGR vs NDRA
ITGR vs NDRA
Side-by-side comparison of Integer Holdings Corporation (ITGR) and ENDRA Life Sciences Inc. (NDRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ITGR and NDRA operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- ITGR is the larger of the two at $3.12B, about 588.9x NDRA ($5.3M).
- Over the past year, ITGR is down 24.8% and NDRA is up 22.4% - NDRA leads by 47.2 points.
- ITGR has been more active in the news (16 items in the past 4 weeks vs 3 for NDRA).
- ITGR has more recent analyst coverage (23 ratings vs 0 for NDRA).
- Company
- Integer Holdings Corporation
- ENDRA Life Sciences Inc.
- Price
- $91.87-0.26%
- $4.32-13.43%
- Market cap
- $3.12B
- $5.3M
- 1M return
- +4.65%
- -10.93%
- 1Y return
- -24.78%
- +22.38%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 16
- 3
- Recent ratings
- 23
- 0
Integer Holdings Corporation
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates in two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and management systems, charging and docking stations, and power supplies for the energy, military, and environmental markets. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. It develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. The company also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Latest ITGR
- Integer to Participate in Truist Securities 2026 MedTech Conference on June 16
- Director Maxwell Martin C was granted 1,967 shares, increasing direct ownership by 9% to 25,106 units (SEC Form 4)
- SEC Form 4 filed by Director Hinrichs James F.
- Director Coyle Michael J was granted 1,967 shares, increasing direct ownership by 145% to 3,322 units (SEC Form 4)
- Director Kapito Aaron was granted 1,967 shares, increasing direct ownership by 144% to 3,338 units (SEC Form 4)
- Director Capps Cheryl C was granted 1,967 shares, increasing direct ownership by 17% to 13,669 units (SEC Form 4)
- Director Jeffers Alvin Tyrone was granted 1,967 shares, increasing direct ownership by 76% to 4,552 units (SEC Form 4)
- Director Antrum Sheila was granted 1,967 shares, increasing direct ownership by 19% to 12,069 units (SEC Form 4)
- Director Passerini Filippo was granted 1,967 shares, increasing direct ownership by 7% to 31,114 units (SEC Form 4)
- Director Flanagan James Francis was granted 1,967 shares, increasing direct ownership by 480% to 2,377 units (SEC Form 4)
Latest NDRA
- ENDRA Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- SEC Form RW filed by ENDRA Life Sciences Inc.
- ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
- SEC Form S-8 filed by ENDRA Life Sciences Inc.
- SEC Form 10-Q filed by ENDRA Life Sciences Inc.
- ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility
- ENDRA Life Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-K filed by ENDRA Life Sciences Inc.
- ENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update